nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—RAF1—liver cancer	0.26	0.591	CbGaD
Dabrafenib—RAF1—Sorafenib—liver cancer	0.183	0.47	CbGbCtD
Dabrafenib—BRAF—liver cancer	0.18	0.409	CbGaD
Dabrafenib—BRAF—Sorafenib—liver cancer	0.153	0.393	CbGbCtD
Dabrafenib—ABCG2—Sorafenib—liver cancer	0.0174	0.0446	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—liver cancer	0.0105	0.027	CbGbCtD
Dabrafenib—CYP2C8—Sorafenib—liver cancer	0.00925	0.0237	CbGbCtD
Dabrafenib—ABCB1—Sorafenib—liver cancer	0.00626	0.0161	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—liver cancer	0.0038	0.00975	CbGbCtD
Dabrafenib—CYP3A4—Sorafenib—liver cancer	0.00375	0.00963	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—liver cancer	0.00228	0.00584	CbGbCtD
Dabrafenib—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000343	0.00401	CcSEcCtD
Dabrafenib—Hypophosphataemia—Epirubicin—liver cancer	0.000341	0.00398	CcSEcCtD
Dabrafenib—Pancreatitis—Sorafenib—liver cancer	0.000329	0.00385	CcSEcCtD
Dabrafenib—Polyp—Epirubicin—liver cancer	0.000325	0.0038	CcSEcCtD
Dabrafenib—Gingival bleeding—Doxorubicin—liver cancer	0.000323	0.00377	CcSEcCtD
Dabrafenib—Abdominal discomfort—Sorafenib—liver cancer	0.000322	0.00377	CcSEcCtD
Dabrafenib—Hypophosphataemia—Doxorubicin—liver cancer	0.000315	0.00368	CcSEcCtD
Dabrafenib—Folliculitis—Epirubicin—liver cancer	0.000315	0.00368	CcSEcCtD
Dabrafenib—Neutropenia—Sorafenib—liver cancer	0.000314	0.00367	CcSEcCtD
Dabrafenib—Hypomagnesaemia—Epirubicin—liver cancer	0.000312	0.00364	CcSEcCtD
Dabrafenib—Polyp—Doxorubicin—liver cancer	0.000301	0.00352	CcSEcCtD
Dabrafenib—Infestation NOS—Sorafenib—liver cancer	0.0003	0.0035	CcSEcCtD
Dabrafenib—Infestation—Sorafenib—liver cancer	0.0003	0.0035	CcSEcCtD
Dabrafenib—Cyst—Epirubicin—liver cancer	0.000296	0.00346	CcSEcCtD
Dabrafenib—Renal failure—Sorafenib—liver cancer	0.000294	0.00344	CcSEcCtD
Dabrafenib—Stomatitis—Sorafenib—liver cancer	0.000292	0.00341	CcSEcCtD
Dabrafenib—Folliculitis—Doxorubicin—liver cancer	0.000291	0.00341	CcSEcCtD
Dabrafenib—Hypomagnesaemia—Doxorubicin—liver cancer	0.000288	0.00337	CcSEcCtD
Dabrafenib—Hypercalcaemia—Epirubicin—liver cancer	0.000285	0.00333	CcSEcCtD
Dabrafenib—Epistaxis—Sorafenib—liver cancer	0.000283	0.0033	CcSEcCtD
Dabrafenib—Cyst—Doxorubicin—liver cancer	0.000274	0.0032	CcSEcCtD
Dabrafenib—Haemoglobin—Sorafenib—liver cancer	0.00027	0.00316	CcSEcCtD
Dabrafenib—Haemorrhage—Sorafenib—liver cancer	0.000269	0.00314	CcSEcCtD
Dabrafenib—Vaginal haemorrhage—Epirubicin—liver cancer	0.000267	0.00313	CcSEcCtD
Dabrafenib—Urinary tract disorder—Sorafenib—liver cancer	0.000266	0.0031	CcSEcCtD
Dabrafenib—Connective tissue disorder—Sorafenib—liver cancer	0.000264	0.00309	CcSEcCtD
Dabrafenib—Urethral disorder—Sorafenib—liver cancer	0.000264	0.00308	CcSEcCtD
Dabrafenib—Hypercalcaemia—Doxorubicin—liver cancer	0.000264	0.00308	CcSEcCtD
Dabrafenib—Rash erythematous—Epirubicin—liver cancer	0.000258	0.00302	CcSEcCtD
Dabrafenib—Rash pustular—Epirubicin—liver cancer	0.000248	0.0029	CcSEcCtD
Dabrafenib—Vaginal haemorrhage—Doxorubicin—liver cancer	0.000247	0.00289	CcSEcCtD
Dabrafenib—Angiopathy—Sorafenib—liver cancer	0.000244	0.00285	CcSEcCtD
Dabrafenib—Immune system disorder—Sorafenib—liver cancer	0.000243	0.00284	CcSEcCtD
Dabrafenib—Rigors—Epirubicin—liver cancer	0.000242	0.00283	CcSEcCtD
Dabrafenib—Mediastinal disorder—Sorafenib—liver cancer	0.000242	0.00283	CcSEcCtD
Dabrafenib—Arrhythmia—Sorafenib—liver cancer	0.00024	0.00281	CcSEcCtD
Dabrafenib—Rash erythematous—Doxorubicin—liver cancer	0.000239	0.0028	CcSEcCtD
Dabrafenib—Alopecia—Sorafenib—liver cancer	0.000238	0.00278	CcSEcCtD
Dabrafenib—Mental disorder—Sorafenib—liver cancer	0.000236	0.00275	CcSEcCtD
Dabrafenib—Malnutrition—Sorafenib—liver cancer	0.000234	0.00274	CcSEcCtD
Dabrafenib—Erythema—Sorafenib—liver cancer	0.000234	0.00274	CcSEcCtD
Dabrafenib—Neoplasm malignant—Epirubicin—liver cancer	0.000232	0.00271	CcSEcCtD
Dabrafenib—Rash pustular—Doxorubicin—liver cancer	0.00023	0.00268	CcSEcCtD
Dabrafenib—Muscle spasms—Sorafenib—liver cancer	0.000225	0.00263	CcSEcCtD
Dabrafenib—Rigors—Doxorubicin—liver cancer	0.000224	0.00262	CcSEcCtD
Dabrafenib—Bone disorder—Epirubicin—liver cancer	0.000219	0.00256	CcSEcCtD
Dabrafenib—Cellulitis—Epirubicin—liver cancer	0.000218	0.00254	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Epirubicin—liver cancer	0.000218	0.00254	CcSEcCtD
Dabrafenib—Anaemia—Sorafenib—liver cancer	0.000216	0.00253	CcSEcCtD
Dabrafenib—Hypocalcaemia—Epirubicin—liver cancer	0.000216	0.00253	CcSEcCtD
Dabrafenib—Neoplasm malignant—Doxorubicin—liver cancer	0.000214	0.00251	CcSEcCtD
Dabrafenib—Leukopenia—Sorafenib—liver cancer	0.00021	0.00245	CcSEcCtD
Dabrafenib—Creatinine increased—Epirubicin—liver cancer	0.000208	0.00243	CcSEcCtD
Dabrafenib—Cough—Sorafenib—liver cancer	0.000204	0.00239	CcSEcCtD
Dabrafenib—Bone disorder—Doxorubicin—liver cancer	0.000203	0.00237	CcSEcCtD
Dabrafenib—Hypertension—Sorafenib—liver cancer	0.000202	0.00236	CcSEcCtD
Dabrafenib—Cellulitis—Doxorubicin—liver cancer	0.000201	0.00235	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000201	0.00235	CcSEcCtD
Dabrafenib—Hypocalcaemia—Doxorubicin—liver cancer	0.0002	0.00234	CcSEcCtD
Dabrafenib—Arthralgia—Sorafenib—liver cancer	0.000199	0.00233	CcSEcCtD
Dabrafenib—Myalgia—Sorafenib—liver cancer	0.000199	0.00233	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000198	0.00231	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000198	0.00231	CcSEcCtD
Dabrafenib—Dry mouth—Sorafenib—liver cancer	0.000195	0.00228	CcSEcCtD
Dabrafenib—Hyperkalaemia—Epirubicin—liver cancer	0.000194	0.00227	CcSEcCtD
Dabrafenib—Creatinine increased—Doxorubicin—liver cancer	0.000192	0.00225	CcSEcCtD
Dabrafenib—Influenza like illness—Epirubicin—liver cancer	0.000192	0.00225	CcSEcCtD
Dabrafenib—Infection—Sorafenib—liver cancer	0.00019	0.00222	CcSEcCtD
Dabrafenib—Nervous system disorder—Sorafenib—liver cancer	0.000187	0.00219	CcSEcCtD
Dabrafenib—Thrombocytopenia—Sorafenib—liver cancer	0.000187	0.00219	CcSEcCtD
Dabrafenib—Skin disorder—Sorafenib—liver cancer	0.000186	0.00217	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000183	0.00214	CcSEcCtD
Dabrafenib—Hyperkalaemia—Doxorubicin—liver cancer	0.00018	0.0021	CcSEcCtD
Dabrafenib—Rash maculo-papular—Epirubicin—liver cancer	0.00018	0.0021	CcSEcCtD
Dabrafenib—Neoplasm—Epirubicin—liver cancer	0.000179	0.00209	CcSEcCtD
Dabrafenib—Influenza like illness—Doxorubicin—liver cancer	0.000178	0.00208	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000174	0.00203	CcSEcCtD
Dabrafenib—Rash maculo-papular—Doxorubicin—liver cancer	0.000166	0.00195	CcSEcCtD
Dabrafenib—Decreased appetite—Sorafenib—liver cancer	0.000166	0.00194	CcSEcCtD
Dabrafenib—Neoplasm—Doxorubicin—liver cancer	0.000166	0.00194	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000165	0.00193	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000165	0.00193	CcSEcCtD
Dabrafenib—Fatigue—Sorafenib—liver cancer	0.000165	0.00193	CcSEcCtD
Dabrafenib—Constipation—Sorafenib—liver cancer	0.000163	0.00191	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Epirubicin—liver cancer	0.000158	0.00185	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Sorafenib—liver cancer	0.000156	0.00183	CcSEcCtD
Dabrafenib—Renal failure acute—Epirubicin—liver cancer	0.000156	0.00182	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000153	0.00179	CcSEcCtD
Dabrafenib—Abdominal pain—Sorafenib—liver cancer	0.000151	0.00177	CcSEcCtD
Dabrafenib—Body temperature increased—Sorafenib—liver cancer	0.000151	0.00177	CcSEcCtD
Dabrafenib—Dermatitis bullous—Epirubicin—liver cancer	0.00015	0.00176	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Doxorubicin—liver cancer	0.000147	0.00171	CcSEcCtD
Dabrafenib—Hyponatraemia—Epirubicin—liver cancer	0.000144	0.00169	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—liver cancer	0.000144	0.00168	CcSEcCtD
Dabrafenib—Pain in extremity—Epirubicin—liver cancer	0.000144	0.00168	CcSEcCtD
Dabrafenib—Hypersensitivity—Sorafenib—liver cancer	0.000141	0.00165	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—liver cancer	0.000139	0.00163	CcSEcCtD
Dabrafenib—Asthenia—Sorafenib—liver cancer	0.000137	0.0016	CcSEcCtD
Dabrafenib—Pruritus—Sorafenib—liver cancer	0.000135	0.00158	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—liver cancer	0.000135	0.00157	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—liver cancer	0.000134	0.00156	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—liver cancer	0.000133	0.00156	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—liver cancer	0.000133	0.00155	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—liver cancer	0.000132	0.00154	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—liver cancer	0.000131	0.00153	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—liver cancer	0.000131	0.00153	CcSEcCtD
Dabrafenib—Diarrhoea—Sorafenib—liver cancer	0.000131	0.00153	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000129	0.00151	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—liver cancer	0.000128	0.0015	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000127	0.00148	CcSEcCtD
Dabrafenib—Dizziness—Sorafenib—liver cancer	0.000126	0.00148	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—liver cancer	0.000125	0.00146	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—liver cancer	0.000124	0.00145	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—liver cancer	0.000122	0.00142	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—liver cancer	0.000122	0.00142	CcSEcCtD
Dabrafenib—Vomiting—Sorafenib—liver cancer	0.000121	0.00142	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—liver cancer	0.000121	0.00142	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—liver cancer	0.000121	0.00141	CcSEcCtD
Dabrafenib—Rash—Sorafenib—liver cancer	0.00012	0.00141	CcSEcCtD
Dabrafenib—Dermatitis—Sorafenib—liver cancer	0.00012	0.00141	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00012	0.0014	CcSEcCtD
Dabrafenib—Headache—Sorafenib—liver cancer	0.00012	0.0014	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—liver cancer	0.000119	0.00139	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000117	0.00137	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—liver cancer	0.000116	0.00136	CcSEcCtD
Dabrafenib—Nausea—Sorafenib—liver cancer	0.000113	0.00133	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—liver cancer	0.000113	0.00132	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—liver cancer	0.000112	0.00131	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—liver cancer	0.000111	0.00129	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—liver cancer	0.000111	0.00129	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—liver cancer	0.000109	0.00127	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—liver cancer	0.000108	0.00126	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—liver cancer	0.000108	0.00126	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—liver cancer	0.000107	0.00126	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—liver cancer	0.000106	0.00123	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—liver cancer	0.000104	0.00122	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—liver cancer	0.000104	0.00121	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—liver cancer	0.000102	0.0012	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—liver cancer	0.000102	0.0012	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—liver cancer	0.000101	0.00118	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—liver cancer	9.99e-05	0.00117	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—liver cancer	9.98e-05	0.00117	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—liver cancer	9.96e-05	0.00116	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—liver cancer	9.94e-05	0.00116	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—liver cancer	9.81e-05	0.00115	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—liver cancer	9.79e-05	0.00114	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—liver cancer	9.77e-05	0.00114	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—liver cancer	9.77e-05	0.00114	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—liver cancer	9.74e-05	0.00114	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—liver cancer	9.66e-05	0.00113	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—liver cancer	9.29e-05	0.00109	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—liver cancer	9.24e-05	0.00108	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—liver cancer	9.2e-05	0.00108	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—liver cancer	9.08e-05	0.00106	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—liver cancer	9.06e-05	0.00106	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—liver cancer	9.04e-05	0.00106	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—liver cancer	9.02e-05	0.00105	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—liver cancer	9.01e-05	0.00105	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—liver cancer	8.98e-05	0.00105	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—liver cancer	8.96e-05	0.00105	CcSEcCtD
Dabrafenib—Chills—Epirubicin—liver cancer	8.92e-05	0.00104	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—liver cancer	8.88e-05	0.00104	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—liver cancer	8.78e-05	0.00103	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—liver cancer	8.71e-05	0.00102	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—liver cancer	8.65e-05	0.00101	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—liver cancer	8.65e-05	0.00101	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—liver cancer	8.59e-05	0.001	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—liver cancer	8.37e-05	0.000978	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—liver cancer	8.34e-05	0.000975	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—liver cancer	8.32e-05	0.000972	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—liver cancer	8.31e-05	0.000971	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—liver cancer	8.29e-05	0.000969	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—liver cancer	8.25e-05	0.000965	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—liver cancer	8.21e-05	0.00096	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—liver cancer	8.15e-05	0.000953	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—liver cancer	8.13e-05	0.00095	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—liver cancer	8.06e-05	0.000942	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—liver cancer	8e-05	0.000936	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—liver cancer	8e-05	0.000936	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—liver cancer	8e-05	0.000935	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—liver cancer	7.74e-05	0.000905	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—liver cancer	7.74e-05	0.000905	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—liver cancer	7.7e-05	0.0009	CcSEcCtD
Dabrafenib—Cough—Epirubicin—liver cancer	7.55e-05	0.000883	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—liver cancer	7.54e-05	0.000882	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—liver cancer	7.47e-05	0.000873	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—liver cancer	7.4e-05	0.000865	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—liver cancer	7.37e-05	0.000861	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—liver cancer	7.37e-05	0.000861	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	7.31e-05	0.000855	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—liver cancer	7.2e-05	0.000842	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—liver cancer	7.17e-05	0.000838	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—liver cancer	7.06e-05	0.000825	CcSEcCtD
Dabrafenib—Infection—Epirubicin—liver cancer	7.01e-05	0.00082	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—liver cancer	6.99e-05	0.000817	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—liver cancer	6.92e-05	0.000809	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—liver cancer	6.91e-05	0.000808	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—liver cancer	6.91e-05	0.000808	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—liver cancer	6.86e-05	0.000802	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—liver cancer	6.83e-05	0.000798	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—liver cancer	6.82e-05	0.000797	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—liver cancer	6.82e-05	0.000797	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	6.77e-05	0.000791	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—liver cancer	6.67e-05	0.000779	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—liver cancer	6.6e-05	0.000771	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—liver cancer	6.53e-05	0.000764	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—liver cancer	6.49e-05	0.000759	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—liver cancer	6.43e-05	0.000752	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—liver cancer	6.41e-05	0.000749	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—liver cancer	6.4e-05	0.000748	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—liver cancer	6.39e-05	0.000747	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—liver cancer	6.35e-05	0.000742	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—liver cancer	6.32e-05	0.000738	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—liver cancer	6.14e-05	0.000718	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—liver cancer	6.1e-05	0.000714	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—liver cancer	6.1e-05	0.000713	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—liver cancer	6.09e-05	0.000712	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—liver cancer	6.04e-05	0.000706	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—liver cancer	5.95e-05	0.000696	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—liver cancer	5.91e-05	0.000691	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—liver cancer	5.77e-05	0.000675	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—liver cancer	5.68e-05	0.000664	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—liver cancer	5.64e-05	0.000659	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—liver cancer	5.63e-05	0.000658	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—liver cancer	5.59e-05	0.000653	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—liver cancer	5.58e-05	0.000653	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—liver cancer	5.58e-05	0.000653	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—liver cancer	5.34e-05	0.000625	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—liver cancer	5.2e-05	0.000608	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—liver cancer	5.16e-05	0.000604	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—liver cancer	5.16e-05	0.000604	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—liver cancer	5.07e-05	0.000592	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—liver cancer	5e-05	0.000584	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—liver cancer	4.83e-05	0.000565	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—liver cancer	4.81e-05	0.000563	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—liver cancer	4.69e-05	0.000548	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—liver cancer	4.67e-05	0.000546	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—liver cancer	4.62e-05	0.00054	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—liver cancer	4.49e-05	0.000525	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—liver cancer	4.47e-05	0.000523	CcSEcCtD
Dabrafenib—Rash—Epirubicin—liver cancer	4.45e-05	0.00052	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—liver cancer	4.45e-05	0.00052	CcSEcCtD
Dabrafenib—Headache—Epirubicin—liver cancer	4.42e-05	0.000517	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—liver cancer	4.32e-05	0.000505	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—liver cancer	4.19e-05	0.00049	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—liver cancer	4.15e-05	0.000486	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—liver cancer	4.12e-05	0.000482	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—liver cancer	4.12e-05	0.000481	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—liver cancer	4.09e-05	0.000478	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—liver cancer	3.88e-05	0.000454	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways—ESR1—liver cancer	4.76e-06	5.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—liver cancer	4.76e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—liver cancer	4.76e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—liver cancer	4.72e-06	5.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—F2—liver cancer	4.7e-06	5.58e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—liver cancer	4.69e-06	5.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCE—liver cancer	4.69e-06	5.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—liver cancer	4.67e-06	5.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CD—liver cancer	4.63e-06	5.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1B—liver cancer	4.62e-06	5.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALDOB—liver cancer	4.59e-06	5.44e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CD—liver cancer	4.59e-06	5.44e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—liver cancer	4.53e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.52e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APC—liver cancer	4.5e-06	5.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CG—liver cancer	4.5e-06	5.34e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP1A1—liver cancer	4.48e-06	5.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APC—liver cancer	4.44e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF2—liver cancer	4.44e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—liver cancer	4.43e-06	5.26e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.41e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HPGDS—liver cancer	4.39e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CRABP1—liver cancer	4.38e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	4.38e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—liver cancer	4.37e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.37e-06	5.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—liver cancer	4.36e-06	5.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—liver cancer	4.29e-06	5.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	4.27e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1A—liver cancer	4.26e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CD—liver cancer	4.23e-06	5.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—liver cancer	4.2e-06	4.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—liver cancer	4.18e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—liver cancer	4.17e-06	4.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—liver cancer	4.15e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP1A1—liver cancer	4.15e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CSF2—liver cancer	4.14e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARA—liver cancer	4.09e-06	4.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—H2AFX—liver cancer	4.09e-06	4.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—liver cancer	4.04e-06	4.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CB—liver cancer	4.04e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—liver cancer	4.04e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CB—liver cancer	4e-06	4.74e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.98e-06	4.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—liver cancer	3.97e-06	4.71e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CD—liver cancer	3.96e-06	4.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.93e-06	4.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSMD10—liver cancer	3.91e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSMA4—liver cancer	3.91e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SERPINE1—liver cancer	3.91e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CD—liver cancer	3.91e-06	4.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—liver cancer	3.87e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SERPINE1—liver cancer	3.86e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—liver cancer	3.86e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—liver cancer	3.86e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HPGDS—liver cancer	3.83e-06	4.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT2—liver cancer	3.81e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—liver cancer	3.8e-06	4.51e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARA—liver cancer	3.79e-06	4.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—liver cancer	3.71e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—liver cancer	3.71e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—liver cancer	3.69e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MTOR—liver cancer	3.69e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CB—liver cancer	3.69e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.68e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CPT1B—liver cancer	3.66e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLUL—liver cancer	3.66e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.6e-06	4.27e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2E1—liver cancer	3.58e-06	4.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—liver cancer	3.57e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—liver cancer	3.57e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—liver cancer	3.54e-06	4.19e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RAF1—liver cancer	3.53e-06	4.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NR1H4—liver cancer	3.53e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—liver cancer	3.53e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—liver cancer	3.51e-06	4.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—liver cancer	3.5e-06	4.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA3—liver cancer	3.47e-06	4.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.47e-06	4.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—liver cancer	3.46e-06	4.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—liver cancer	3.45e-06	4.09e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—liver cancer	3.45e-06	4.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—liver cancer	3.43e-06	4.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—liver cancer	3.42e-06	4.06e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMA4—liver cancer	3.41e-06	4.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMD10—liver cancer	3.41e-06	4.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—liver cancer	3.41e-06	4.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—liver cancer	3.41e-06	4.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—liver cancer	3.39e-06	4.02e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—liver cancer	3.38e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—liver cancer	3.38e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK14—liver cancer	3.36e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYCS—liver cancer	3.35e-06	3.97e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT2—liver cancer	3.32e-06	3.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—liver cancer	3.3e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—liver cancer	3.29e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GGT1—liver cancer	3.29e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT1—liver cancer	3.29e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—liver cancer	3.27e-06	3.88e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—liver cancer	3.27e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	3.25e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—liver cancer	3.25e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—liver cancer	3.25e-06	3.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—liver cancer	3.24e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—liver cancer	3.2e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—liver cancer	3.19e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA4—liver cancer	3.17e-06	3.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—liver cancer	3.17e-06	3.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—liver cancer	3.17e-06	3.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—liver cancer	3.15e-06	3.74e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—liver cancer	3.13e-06	3.72e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2E1—liver cancer	3.12e-06	3.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—liver cancer	3.12e-06	3.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—liver cancer	3.11e-06	3.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—liver cancer	3.11e-06	3.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA2—liver cancer	3.09e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—liver cancer	3.09e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—liver cancer	3.08e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—liver cancer	3.08e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—liver cancer	3.06e-06	3.63e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—liver cancer	3.04e-06	3.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—liver cancer	3.03e-06	3.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—liver cancer	3.02e-06	3.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—liver cancer	3e-06	3.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—liver cancer	3e-06	3.55e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—liver cancer	2.99e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA1—liver cancer	2.98e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—liver cancer	2.95e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—liver cancer	2.95e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAT2—liver cancer	2.95e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	2.94e-06	3.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—liver cancer	2.93e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYCS—liver cancer	2.92e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—liver cancer	2.91e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—liver cancer	2.91e-06	3.45e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GGT1—liver cancer	2.86e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT1—liver cancer	2.86e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—liver cancer	2.85e-06	3.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—liver cancer	2.85e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDOB—liver cancer	2.83e-06	3.35e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—liver cancer	2.82e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—liver cancer	2.78e-06	3.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—liver cancer	2.74e-06	3.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—liver cancer	2.71e-06	3.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—liver cancer	2.71e-06	3.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CRABP1—liver cancer	2.7e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—liver cancer	2.69e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—liver cancer	2.69e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—liver cancer	2.68e-06	3.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—liver cancer	2.66e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—liver cancer	2.66e-06	3.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—liver cancer	2.63e-06	3.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—liver cancer	2.57e-06	3.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A1—liver cancer	2.57e-06	3.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—liver cancer	2.54e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—liver cancer	2.49e-06	2.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—liver cancer	2.48e-06	2.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—liver cancer	2.47e-06	2.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—liver cancer	2.46e-06	2.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—liver cancer	2.45e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—liver cancer	2.45e-06	2.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—liver cancer	2.45e-06	2.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—liver cancer	2.44e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—liver cancer	2.44e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—liver cancer	2.4e-06	2.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—liver cancer	2.39e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—liver cancer	2.39e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—liver cancer	2.36e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—liver cancer	2.36e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARA—liver cancer	2.35e-06	2.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—liver cancer	2.29e-06	2.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—liver cancer	2.28e-06	2.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—liver cancer	2.26e-06	2.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—liver cancer	2.25e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A1—liver cancer	2.24e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—liver cancer	2.24e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—liver cancer	2.19e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—liver cancer	2.19e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—liver cancer	2.18e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—liver cancer	2.14e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—liver cancer	2.13e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—liver cancer	2.11e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.11e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—liver cancer	2.1e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMD10—liver cancer	2.1e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMA4—liver cancer	2.1e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—liver cancer	2.09e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—liver cancer	2.08e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—liver cancer	2.08e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—liver cancer	2.07e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—liver cancer	2.07e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARA—liver cancer	2.05e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT2—liver cancer	2.04e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—liver cancer	2.03e-06	2.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—liver cancer	2.02e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—liver cancer	2.01e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—liver cancer	2.01e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—liver cancer	1.99e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—liver cancer	1.99e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—liver cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—liver cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2E1—liver cancer	1.92e-06	2.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—liver cancer	1.92e-06	2.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—liver cancer	1.86e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—liver cancer	1.86e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—liver cancer	1.84e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—liver cancer	1.84e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—liver cancer	1.84e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYCS—liver cancer	1.8e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—liver cancer	1.77e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GGT1—liver cancer	1.76e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT1—liver cancer	1.76e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—liver cancer	1.76e-06	2.08e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—liver cancer	1.75e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—liver cancer	1.72e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—liver cancer	1.71e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—liver cancer	1.71e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—liver cancer	1.7e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—liver cancer	1.69e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—liver cancer	1.64e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—liver cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—liver cancer	1.58e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—liver cancer	1.56e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—liver cancer	1.54e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—liver cancer	1.54e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—liver cancer	1.52e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—liver cancer	1.52e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—liver cancer	1.46e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—liver cancer	1.45e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—liver cancer	1.41e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.38e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—liver cancer	1.35e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—liver cancer	1.35e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—liver cancer	1.34e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—liver cancer	1.29e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—liver cancer	1.29e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARA—liver cancer	1.26e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—liver cancer	1.24e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—liver cancer	1.19e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.08e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—liver cancer	1.04e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—liver cancer	9.51e-07	1.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—liver cancer	9.41e-07	1.12e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—liver cancer	9.39e-07	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—liver cancer	8.29e-07	9.83e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—liver cancer	8.2e-07	9.73e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—liver cancer	7.69e-07	9.12e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—liver cancer	6.7e-07	7.95e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—liver cancer	5.05e-07	5.99e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—liver cancer	4.13e-07	4.9e-06	CbGpPWpGaD
